205 related articles for article (PubMed ID: 30642440)
21. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
22. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
[TBL] [Abstract][Full Text] [Related]
24. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
25. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
Zhao S; Zhu S; Lei X; Xu D; Shi T; Chen Q; Ren F; Chen G; Huang D; Xu S
Thorac Cancer; 2021 Oct; 12(20):2815-2818. PubMed ID: 34405544
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K
J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029
[TBL] [Abstract][Full Text] [Related]
27. Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation.
Brosseau S; Gounant V; Naltet C; Théou-Anton N; Cazes A; Smonig R; Neuville M; Khalil A; Mikail N; Meignin V; Bergeron A; Zalcman G
Clin Lung Cancer; 2018 Jan; 19(1):e57-e61. PubMed ID: 28844392
[No Abstract] [Full Text] [Related]
28. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
29. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
30. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
31. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.
Lee CJ; Schöffski P; Modave E; van Wezel T; Boeckx B; Sufliarsky J; Gelderblom H; Blay JY; Debiec-Rychter M; Sciot R; Bovée JVMG; Lambrechts D; Wozniak A
Clin Cancer Res; 2021 Dec; 27(24):6737-6748. PubMed ID: 34551905
[TBL] [Abstract][Full Text] [Related]
33. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
34. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
Lambros L; Guibourg B; Uguen A
Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
[No Abstract] [Full Text] [Related]
35. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
[No Abstract] [Full Text] [Related]
37. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
38. A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Li J; Liu L; Zhang Q; Huang Y; Zhang Y; Gan X; Liu S; Yue Z; Wei Y
Medicine (Baltimore); 2020 Jun; 99(26):e20725. PubMed ID: 32590748
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
40. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
